PYLON
LIVE

Serial Number

88907223

Owner

Access Medical Systems

Attorney

Andrew T. Pettit

Filing Date

May 8, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PYLON Trademark

Serial Number: 88907223 • Registration: 6713900

PYLON is a trademark filed by Access Medical Systems on May 8, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Access Medical Systems (7 trademarks)

1455 Adams Dr 1322
Menlo Park, CA 94025

Entity Type: 03

Trademark Details

Filing Date

May 8, 2020

Registration Date

April 26, 2022

Published for Opposition

April 13, 2021

Goods & Services

Laboratory apparatus, namely, immunoassay analyzers for measuring presence and/or concentration of biomolecules in a sample through interferometry; laboratory apparatus, namely, immunoassay analyzers for studying biomolecules in blood, serum, or plasma samples through interferometry; interferometric laboratory apparatus, namely, automated immunoassay analyzers for scientific, research, or diagnostic use, not for medical purposes; interferometric laboratory apparatus, namely, immunochemistry analyzers for performing immunoassays on body fluids; automated research laboratory analyzer for clinical chemistry applications in the nature of measuring, testing and analyzing blood and other bodily fluids through interferometry; laboratory instruments for analyzing biomolecules at different stages of therapeutic development through interferometry; interferometric instruments being interferometers for use in scientific, research, or diagnostic procedures, not for medical purposes; laboratory imaging instruments for studying biomolecules in the nature of proteins, ligands, and nucleic acids through interferometry, for research purposes; automated medical laboratory analyzer for detecting the presence or concentration of biomolecules through interferometry

Reagents for reacting with biomolecules for medical use; reagents for medical use; diagnostic reagents for medical use; diagnostic reagents, buffers, and preparations for medical use; biochemical reagents used for medical purposes for detecting and/or analyzing antigens, antibodies, proteins, ligands, or nucleotides; chemicals, namely, antibody reagents used for the detection of antigens or antibodies in liquid, cell, and tissue analysis for in vitro diagnostic use for medical purposes; diagnostic preparations for medical or veterinary purposes, namely, reagents, buffers, and preparations for altering the nature of a probe to which biomolecules bind over the course of a diagnostic procedure; diagnostic preparations for medical or veterinary purposes, namely, reagents, buffers, and preparations for modifying a probe to which biomolecules bind for diagnostic purposes

Reagents for reacting with biomolecules for scientific use; reagents for scientific use; reagents for reacting with biomolecules for research use; reagents for research use; diagnostic reagents for scientific research use; diagnostic reagents, buffers, and preparations, except for medical and veterinary use; biochemical reagents used for non-medical purposes for detecting and/or analyzing antigens, antibodies, proteins, ligands, or nucleotides; laboratory chemicals, namely, antibody reagents used for the detection of antigens or antibodies in liquid, cell, and tissue analysis for in vitro diagnostic use; diagnostic preparations other than for medical or veterinary purposes, namely, reagents, buffers, and preparations for altering the nature of a probe to which biomolecules bind over the course of a diagnostic procedure; diagnostic preparations other than for medical or veterinary purposes, namely, reagents, buffers, and preparations for modifying a probe to which biomolecules bind for diagnostic purposes

Medical diagnostic apparatus, namely, immunoassay analyzers for analyzing body fluids through the measuring of light interference; medical diagnostic apparatus, namely, immunoassay analyzers for studying biomolecules in blood, serum, or plasma samples for medical purposes; medical diagnostic apparatus, namely, automated immunoassay analyzers for medical use; medical diagnostic apparatus, namely, immunochemistry analyzers for performing immunoassays on body fluids; interferometric instruments in the nature of interferometers for medical purposes, for use in medical procedures; medical diagnostic imaging instruments for studying biomolecules, including proteins, ligands, and nucleic acids, for medical purposes; medical diagnostic instruments for analyzing body fluids through interferometry; medical diagnostic tool for investigating scientific questions and conducting tests for medical purposes

Filing History

REGISTERED-PRINCIPAL REGISTER
Apr 26, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 22, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 21, 2022 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 12, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 11, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 11, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 10, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 10, 2022 GNRT
SU - NON-FINAL ACTION - WRITTEN
Jan 10, 2022 CNRT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 15, 2021 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Dec 14, 2021 SUPC
SOU EXTENSION 1 GRANTED
Dec 14, 2021 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 13, 2021 AITU
USE AMENDMENT FILED
Dec 3, 2021 IUAF
SOU EXTENSION 1 FILED
Dec 3, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 3, 2021 EEXT
TEAS STATEMENT OF USE RECEIVED
Dec 3, 2021 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 8, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 13, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 13, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 10, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 9, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 10, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 10, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 10, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 4, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 20, 2020 NWOS
NEW APPLICATION ENTERED
May 12, 2020 NWAP